Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Izuralimab - Xencor

Next Previous
Drug Profile

Izuralimab - Xencor

Alternative Names: PD-1 x ICOS; XmAb-104; XmAb-23104

Latest Information Update: 01 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Inducible T-cell co-stimulator protein agonists; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Sarcoma; Solid tumours

Most Recent Events

  • 19 Jul 2024 Memorial Sloan Kettering Cancer Center terminates phase II trial in Sarcoma (Late-stage disease, Metastatic disease) in USA (IV) (NCT05879185)
  • 15 Feb 2024 Xencor completes phase-I DUET-3 clinical trials in Solid tumours (Late-stage disease) in USA (IV) (NCT03752398)
  • 07 Nov 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top